The PDUFA date of January 21, 2027, is the next major catalyst. Traders should monitor for any FDA advisory committee meeting announcements or review updates in the coming months. A positive decision could be transformative for Dyne, while a complete response letter would be a severe setback.
Price Chart
Executive Summary
Dyne Therapeutics announced FDA acceptance of its BLA for z-rostudirsen (DYNE-251) for Duchenne muscular dystrophy amenable to exon 51 skipping, granted Priority Review with a PDUFA target date of January 21, 2027. The company expects a potential U.S. launch in Q1 2027 if approved, marking a significant regulatory milestone for this clinical-stage biotech.
Key Facts
- FDA accepted BLA for z-rostudirsen (DYNE-251) for DMD exon 51 skipping
- Priority Review granted with PDUFA target action date of January 21, 2027
- Company expects potential U.S. launch in first quarter of 2027, assuming approval
Financial Impact
No financial figures provided in the filing; approval could unlock significant revenue potential in DMD market
Risk Factors
- FDA may not approve the BLA or may require additional clinical data
- Potential delays in review timeline or advisory committee outcomes
- Competition from existing DMD therapies (e.g., Exondys 51, Vyondys 53) and other exon-skipping candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-308343 |
| Document: 0001193125-26-308343-index-headers.html | 0001193125-26-308343 |
| Document: 0001193125-26-308343-index.html | 0001193125-26-308343 |
| Document: 0001193125-26-308343.txt | 0001193125-26-308343 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.20 (+41.87%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.20 (−41.87%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.20 (+40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.20 (−40.92%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.20 (+34.51%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.20 (−35.18%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.20 (−30.24%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.20 (+31.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access